In­cyte flips Chi­na rights of Macro­Gen­ic­s' PD-1 to an am­bi­tious Zai Lab keen on leapfrog­ging pi­o­neers with com­bos

Amid the pro­lif­er­a­tion of check­point in­hibitors in Chi­na, Zai Lab is bring­ing in one more PD-1 agent in a move to in­stall what has be­come an es­sen­tial part of any im­muno-on­col­o­gy pipeline.

Orig­i­nal­ly de­vel­oped by Macro­Gen­ics and now con­trolled by In­cyte, IN­CM­GA0012 is in Zai Lab’s view a glob­al­ly com­pet­i­tive as­set that can stand as both a monother­a­py and com­bi­na­tion in­gre­di­ent.

“The mol­e­c­u­lar pro­file is quite sim­i­lar to Keytru­da and Op­di­vo,” said Yongjiang Hei, Zai Lab’s CSO in on­col­o­gy, on an in­vestor call.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.